SAWC

Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Diabetic foot, Financial statement, PIN, Ulcer, Symposium, Sale, KNE, Pivot, Credit, Leg, SAWC, US FDA, Patent, FDA, Government, Food

WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.

Key Points: 
  • WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.
  • On December 20, 2023, Kane Biotech announced that it received a non-binding offer for its interest in STEM Animal Health.
  • Gross profit for the fourth quarter of 2023 was $398,234, an increase of 24% compared to $320,653 for the fourth quarter ended December 31, 2022.
  • Loss for the fourth quarter of 2023 was ($1,611,894), an increase of 92% compared to ($838,150) for the quarter ended December 31, 2022.

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 21, 2024
Burn, Tax, Debridement, Patient, EWMA, Bank statement, Eschar, Investment, SAWC, Therapy, Depreciation, European Commission, Phase, BCC, Research, Supplement, Wound, EMA, GMP, HERE, Safety, CMS, BLA, Eastern Time Zone, Food, Bromelain (pharmacology), WBP, Development, PMI, WHS, Adjustment, FDA, BMCI, Forecasting, Symposium, Incidence, BSV, Basal-cell carcinoma, Operating cost, European Wound Management Association, Table, Event, Medicare, Pharmaceutical industry

YAVNE, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Revenue: Revenue for the fourth quarter 2023 was $5.3 million, compared to $11.6 million in the fourth quarter of 2022.
  • Research and development expenses in the fourth quarter 2023 were $1.8 million compared to $2.7 million in the fourth quarter of 2022.
  • Selling, general, and administrative expenses in the fourth quarter 2023 were $2.8 million, compared to $3.0 million in the fourth quarter of 2022.
  • Operating Results: Operating loss in the fourth quarter of 2023 was $3.9 million, compared to an operating profit of $2.1 million in the fourth quarter of 2022.

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

Retrieved on: 
Monday, February 12, 2024
Incidence, FDA, EWMA, Safety, Debridement, Wound, WBP, Patient, Symposium, WHS, Granulation tissue, Disease, SAWC, NSS, European Wound Management Association, Wound healing

SANTYL is currently the market-leading enzymatic debridement product, with more than $360 million in estimated annual sales in the United States.

Key Points: 
  • SANTYL is currently the market-leading enzymatic debridement product, with more than $360 million in estimated annual sales in the United States.
  • Ofer Gonen, CEO of MediWound said, “These head-to-head results position EscharEx to become the market leader in enzymatic agents for the treatment of chronic wounds.
  • All are achieved within a short time frame to facilitate early wound closure, a major benefit for patients suffering from chronic non-healing wounds.
  • The incidence of achieving WBP throughout the study was 78.3% (95% CI = 63.6-89.1) for EscharEx vs. 37.5% for SANTYL (95% CI=8.5-75.5); p=0.03.

Kane Biotech Announces Improved Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 28, 2023
SAWC, Private, Sale, Credit, Government, FDA, Pivot, Blood, Financial statement, KNE, PHMB, Symposium, Wound healing

WINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results.

Key Points: 
  • WINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results.
  • Gross profit for the third quarter of 2023 was $315,265, an increase of 17% compared to $269,740 for the quarter ended September 30, 2022.
  • Detailed financial information about Kane Biotech can be found in its September 30, 2023 Financial Statements and Management Discussion and Analysis on SEDAR and the Company’s website.
  • On November 16, 2023, Kane Biotech announced that Dr. John Coleman had been appointed to the Board of Directors of Kane Biotech effective immediately.

Arch Therapeutics Provides Year End Operational Update

Retrieved on: 
Thursday, November 9, 2023
SAWC, HCPCS, Food, Innovation, Medicare, Arch, OTCQB, Foot, AC5, Symposium, Therapy, Centers for Medicare & Medicaid Services, CMS, Wound healing, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Mobile phone, Health insurance, A2020

FRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”).

Key Points: 
  • FRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”).
  • A more detailed summary of key milestones and achievements from the fiscal year ended September 30, 2023 is provided below.
  • At SAWC Spring 2023, Arch introduced the theme “Experience the Difference” to highlight AC5’s technology, application, wound coverage, and efficacy.
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.

Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum

Retrieved on: 
Thursday, November 2, 2023
SAWC, Infection, Wound healing, Biotechnology, Symposium, Partnership, KNE, PHMB

WINNIPEG, Manitoba, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) in partnership with ProgenaCare Global LLP (“ProgenaCare”) today announces the launch of the newly rebranded revyve™ Antimicrobial Wound Gel (formerly coactiv+™ Antimicrobial Wound Gel).

Key Points: 
  • WINNIPEG, Manitoba, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) in partnership with ProgenaCare Global LLP (“ProgenaCare”) today announces the launch of the newly rebranded revyve™ Antimicrobial Wound Gel (formerly coactiv+™ Antimicrobial Wound Gel).
  • “We are excited to share this cutting-edge product and the new revyve™ brand with the larger wound care community.
  • The product rebranding is being unveiled as part of Kane’s participation in the Symposium on Advanced Wound Care (SAWC) Fall forum.
  • During this conference, Kane Biotech and ProgenaCare will present along with other important voices in the Biotech and Wound Care sectors.

MIMEDX to Highlight Published Data at SAWC Fall

Retrieved on: 
Thursday, November 2, 2023
Faculty, Exhibition, SAWC, Debridement, Treatment, Data, Symposium, DRS, Monika Boehm-Tettelbach

MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place November 2-5 in Las Vegas, NV.

Key Points: 
  • MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place November 2-5 in Las Vegas, NV.
  • In addition, the Company will participate in the conference’s exhibition at booth number 511.
  • These faculty presenters will also discuss their clinical experiences with the Company’s recently launched tri-layer placental allograft, EPIEFFECT®.
  • This effort further reinforces the MIMEDX commitment to clinical and scientific evidence and continues to add to the robust portfolio of published evidence supporting the use of Purion® processed human placental allografts.

Clinical Consensus on Kerecis Fish-Skin Grafts to be Presented at the SAWC Wound Conference

Retrieved on: 
Friday, November 3, 2023
Surgery, Medical Devices, Alternative Medicine, Other Health, Health, Iceland, SAWC, VLU, Dicarboxylic acid, DFU, Wound healing, Use, Icahn School of Medicine at Mount Sinai, Treatment, Skin, CWSP, Julius, Multimedia, DPM, Abstract, Caesars Palace, Whaling, MD, Kerecis

SAWC – Kerecis today announced the publication of a multi-disciplinary clinical consensus about the utilization of fish skin grafts on complex wounds.

Key Points: 
  • SAWC – Kerecis today announced the publication of a multi-disciplinary clinical consensus about the utilization of fish skin grafts on complex wounds.
  • The consensus paper will be presented at a CME/CPME/CE-accredited symposium, which will take place Saturday, November 4, from 11:30 am to 12:30 pm in Milano VII-VIII, Caesars Palace, Las Vegas at the SAWC wound conference.
  • View the full release here: https://www.businesswire.com/news/home/20231103279415/en/
    Kerecis' fish-skin grafts are available in various shapes and sizes, such as Kerecis Shield, as shown.
  • The SAWC conference accepted 36 investigator-initiated poster abstracts that discuss the use of fish-skin grafts in various types of wounds and reconstructive operations.

12 Posters and Presentations Featuring MolecuLight to be Presented at the SAWC Fall 2023 Conference

Retrieved on: 
Thursday, November 2, 2023
LAS, SAWC, Wound healing, Milan, MD, RN, CWS, Madigan Army Medical Center, Symposium, University, Hyperbaric medicine, Dot, Patient, DX, Nursing, Medical device, Medical imaging, Powder metallurgy

TORONTO and LAS VEGAS, Nov. 2, 2023 /PRNewswire/ - MolecuLight Inc ., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that MolecuLight data will be presented in 12 clinical posters and presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2023 .

Key Points: 
  • TORONTO and LAS VEGAS, Nov. 2, 2023 /PRNewswire/ - MolecuLight Inc ., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that MolecuLight data will be presented in 12 clinical posters and presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2023 .
  • The results to be presented include new data from recent investigations using MolecuLight device from over 1,500 patients.
  • The international conference is being hosted from November 2 - 5, 2023 in Las Vegas, Nevada, and is one of the largest multidisciplinary meetings of wound care professionals in the world.
  • "We are proud to see once again abundant and consistently favorable outcomes being presented by MolecuLight imaging platform users at this week's SAWC conference", says Anil Amlani, CEO of MolecuLight.

12 Posters and Presentations Featuring MolecuLight to be Presented at the SAWC Fall 2023 Conference

Retrieved on: 
Thursday, November 2, 2023
LAS, SAWC, Wound healing, Milan, MD, RN, CWS, Madigan Army Medical Center, Symposium, University, Hyperbaric medicine, Dot, Patient, DX, Nursing, Medical device, Medical imaging, Powder metallurgy

TORONTO and LAS VEGAS, Nov. 2, 2023 /PRNewswire/ --  MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that MolecuLight data will be presented in 12 clinical posters and presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2023. The results to be presented include new data from recent investigations using MolecuLight device from over 1,500 patients. The international conference is being hosted from November 2 - 5, 2023 in Las Vegas, Nevada, and is one of the largest multidisciplinary meetings of wound care professionals in the world."We are proud to see once again abundant and consistently favorable outcomes being presented by MolecuLight imaging platform users at this week's SAWC conference", says Anil Amlani, CEO of MolecuLight. "The volume of our clinical evidence continues to grow and confirms that MolecuLight improves healing outcomes. Our devices inform the appropriate use of antibiotics and help empower patients during the treatment and recovery of their wounds. We are particularly motivated by of our impactful clinical results in vulnerable patient populations that suffer from health care inequities. Our device has proven to be an equitable diagnostic tool that delivers quality results for patients of all skin tones. This sets us apart and makes us part of the solution, and we couldn't be more proud of this." "Good wound hygiene is a game-changer for taking wound care to the next level and boosting those outcomes. I always say, 'Clean it like you mean it', but we can only clean what we can see. MolecuLight is an objective tool that, for the first time, allows providers to visualize in real-time and more effectively remove bacterial burden that is otherwise invisible to the naked eye," says Dot Weir, RN, CWON, CWS, wound care nurse at Saratoga Hospital Center for Wound Healing and Hyperbaric Medicine in Saratoga Springs, New York and Co-Chair of the Symposium on Advanced Wound Care (SAWC). Dot is speaking at a hands-on pre-conference workshop showing how MolecuLight can be used to guide and improve wound hygiene practices. "We can and should do better. The MolecuLight device is evidence-backed, equitable for all patients, and is instrumental in the care of every single patient who walks through our doors. This amazing piece of hand-held technology is revolutionizing the way we clean wounds. I can't imagine delivering the highest quality of care without it."

Key Points: 
  • TORONTO and LAS VEGAS, Nov. 2, 2023 /PRNewswire/ -- MolecuLight Inc ., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that MolecuLight data will be presented in 12 clinical posters and presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2023 .
  • The results to be presented include new data from recent investigations using MolecuLight device from over 1,500 patients.
  • The international conference is being hosted from November 2 - 5, 2023 in Las Vegas, Nevada, and is one of the largest multidisciplinary meetings of wound care professionals in the world.
  • "We are proud to see once again abundant and consistently favorable outcomes being presented by MolecuLight imaging platform users at this week's SAWC conference", says Anil Amlani, CEO of MolecuLight.